Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.53 |
| ▸ | RBP4 | P02753 | 1/20 | 0.53 |
| ▸ | HRH4 | Q9H3N8 | 14/20 | 0.50 |
| ▸ | ACACB | O00763 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.48 |
| ▸ | HTR2C | P28335 | 3/20 | 0.45 |
| ▸ | HTR2A | P28223 | 2/20 | 0.45 |
| ▸ | HTR2B | P41595 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17748980 | 0.91 | ADRB1 (0.58) | ADRB1RBP4HRH4ACACBHTR2C | |
| SCHEMBL15662899 | 0.84 | RBP4 (0.45) | ADRB1RBP4HRH4ACACBHRH3 | |
| SCHEMBL27851172 | 0.81 | HRH4 (0.69) | HRH4HRH3 | |
| SCHEMBL6830334 | 0.80 | SYK (0.51) | ADRB1RBP4ACACB | |
| SCHEMBL6830336 | 0.80 | SYK (0.51) | ADRB1RBP4ACACB | |
| SCHEMBL14923154 | 0.79 | ADRB1 (0.64) | ADRB1RBP4HTR2CHTR2AHTR2B | |
| SCHEMBL19658658 | 0.79 | ACACB (0.54) | ADRB1RBP4ACACB | |
| SCHEMBL13082994 | 0.78 | ADRB1 (0.56) | ADRB1RBP4ACACBHTR2CHTR2A | |
| SCHEMBL17753021 | 0.78 | ADRB1 (0.56) | ADRB1RBP4ACACBHTR2CHTR2A | |
| SCHEMBL344771 | 0.77 | ADRB1 (0.55) | ADRB1RBP4ACACBHTR2CHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2012-01-19 | — | — | US | disclosed |
| EP-2356108-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010055267-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | INTS9, CDK8, SCN8A | ADRB1 1968/4885RBP4 2582/4885HRH4 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.